Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07672782 · ClinicalTrials.gov registry record · Phase 2
Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva
A Phase 2 study, sponsored by GOG Foundation.
- Not yet
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT07672782: Clinical Trial Phase 2 study, sponsored by GOG Foundation.
NCT07672782 is a Phase 2 study that has not yet begun recruiting, run by GOG Foundation. The registered enrollment target is 28 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07672782, a Phase 2 study, has not yet begun recruiting, sponsored by GOG Foundation.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
This is an open-label, single arm, phase 2 study designed to evaluate the efficacy of tisotumab vedotin in participants with recurrent or metastatic squamous cell carcinoma of the vulva by estimating the objective response rate. Patients will receive tisotumab vedotin every 3 weeks (21 days plus or minus 3 days). Treatment will continue until either unacceptable toxicity, progression of disease, or investigator/patient request for withdrawal.
Primary Outcome
Complete or partial objective tumor response as measured by CT scan, PET-CT or MRI and assessed by RECIST v. 1.1 criteria
Interventions
- DRUG Tisotumab Vedotin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2026-11 |
| Est. Completion | 2029-12 |
| Phase | Phase 2 |
What is known before NCT07672782 opens enrollment
NCT07672782 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 1 intervention - of which Tisotumab Vedotin is the first listed.
NCT07672782 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07672782 about?
NCT07672782 is a clinical study titled "Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva". This is an open-label, single arm, phase 2 study designed to evaluate the efficacy of tisotumab vedotin in participants with recurrent or metastatic squamous cell carcinoma of the vulva by estimating the objective response rate. Patients will receive tisotumab vedotin every 3 weeks (21 days plus or...
What is the current status of trial NCT07672782?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2026-11. Estimated completion is 2029-12.
What interventions are being tested in trial NCT07672782?
The interventions under investigation include: Tisotumab Vedotin (DRUG).
Who is sponsoring clinical trial NCT07672782?
This trial is sponsored by GOG Foundation, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07672782's enrollment target sits among peer trials
28 1677th of 2000 higher than 304 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia